Company news
Annexin Pharmaceuticals Ab (OMXSTO:ANNX) news
Annexin Pharmaceuticals Ab news releases on 6ix. Latest, Aug 20, 2026: Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin…
Press releases & updates
Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV
August 20, 2026
Annexin's rights issue 98 percent subscribed
July 3, 2026
Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million
June 3, 2026
Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study
May 11, 2026
Annexin Pharmaceuticals : secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026
April 13, 2026
Annexin advances phase IIa study by initiating patient treatment
December 9, 2025
Annexin gets green light for phase IIa study in diabetic retinopathy
August 13, 2025
Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO
August 7, 2025
Annexin's rights issue 100 percent subscribed, top guarantee commitments included, and resolution on directed issue to guarantors
March 26, 2025
The subscription period in Annexin Pharmaceuticals’ rights issue begins today
March 7, 2025
Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue
March 6, 2025